Glenmark Pharmaceuticals today announced receipt of final approval from the US health regulator for its generic version of AstraZeneca’s Xylocaine ointment.
The approval given by the US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc USA (Glenmark) is for Lidocaine ointment USP, 5 per cent, the company said in a statement.
Citing IMS Health sales data for the 12-month period ending July 2016, the company said Xylocaine ointment, 5 per cent achieved annual sales of approximately $373.0 million.
Glenmark’s current portfolio consists of 109 products authorised for distribution in the US and 62 ANDAs pending approval with the USFDA.
In addition to these internal filings, Glenmark said it is continuing to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.